Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Grp LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 195.00p 194.00p 196.00p 195.00p 195.00p 195.00p 740 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.2 -18.0 - 119.61

Diurnal Grp Share Discussion Threads

Showing 26 to 49 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
21/3/2018
07:23
HTTP://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/hardman---co--new-capital-funds-commercial-plans/201803210715023590I/ HTTP://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/21.03.18-capital-increase-to-support-commercial-plans.pdf
gersemi
14/3/2018
08:50
Placing at 190p - £11m
gersemi
28/2/2018
11:39
As at 24-8-2017 IP Group plc (including subsidiaries and associates) 23,808,100 45.5% Finance Wales plc 11,534,888 22.1% Invesco Limited 6,527,777 12.5% Oceanwood Capital Management LLP 3,472,222 8.1% TOTAL - 88.2% plus dirs have about 3.4% No wonder the totals on each side of the bid/ask are only 3500 shrs each side....and that also it moves on almost any whiff of buying! f
fillipe
28/2/2018
11:33
Investors Chronicle this week called Diurnal one of Britain's most exciting young companies .Also said as big Pharma lose patent protection takeover activity could increase
pmeldrum
28/2/2018
10:05
Don't think many shares in the public domain?
divinessence
28/2/2018
10:03
Recent RNS ... $415m per annum Japan alone. No wonder share price is climbing. The Alkindi(R) patent, entitled "Treatment of Adrenal Insufficiency", is a pharmaceutical composition-of-matter patent protecting Alkindi(R) 's proprietary formulation as a treatment for adrenal insufficiency in paediatric and elderly adult patients. The patent provides in-market protection until 2032. The Chronocort(R) patent, entitled "Hydrocortisone Controlled Release Formulation", protects the product as a modified-release hydrocortisone formulation. The patent provides in-market protection until 2033. The US and UK counterparts for these patents have already been granted. These patents provide Diurnal with a proprietary position for Alkindi(R) and Chronocort(R) in Japan, where the Company intends to secure a local distribution partner. Japan represents a significant market opportunity for Diurnal with the country being the third largest market for pharmaceutical products after the US and Europe. The Company estimates that there are around 6,700 patients with congenital adrenal hyperplasia and around 58,000 with adrenal insufficiency eligible for treatment with Alkindi(R) and Chronocort(R) in Japan, providing an estimated total market opportunity for Alkindi(R) and Chronocort(R) of approximately $415 million per annum.
divinessence
28/2/2018
09:54
And another nice small uptick, with 211p paid 0933hrs today - after a string of 208p's. It's starting to look as though 250p can be seen with some ease, in the crosshairs. f
fillipe
27/2/2018
18:03
Yes, a good rise today...and all on quite small. f
fillipe
27/2/2018
15:49
A nice quiet thread and continuous appreciation of share price , may this continues
modform
19/2/2018
08:52
RNS out today....further progress and a nice uptick in the share price on extremely small. Heaven only knows how far the share price will streak upwards as commercialisation is fully realised. f
fillipe
02/1/2018
13:20
Its because date for approval is not that far away - FEB. 2018. So few free floats and the prospect of revenues in 2Q 2018 should propel this to £3+ fairly quickly. I added today.
divinessence
02/1/2018
12:26
DNL being bought, today. f
fillipe
02/1/2018
12:26
hxxp://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19-12-17-diurnal.pdf
fillipe
20/12/2017
22:56
fillipe you can post the link please?
divinessence
19/12/2017
16:11
Check out Investegate today for the RNS of Hardman's new research note on DNL. f
fillipe
18/12/2017
14:09
That 5K is a BUY! So is 2.775K, both buys! PI's haven't cottoned on to this yet. Is it only 17% free float?
divinessence
18/12/2017
11:29
Numis BUY .... tp = 185p. https://www.investegate.co.uk/News/broker-forecast---numis-issues-a-broker-note-on-diurnal-group-plc/780184/ f
fillipe
15/12/2017
14:49
Excellent first class news today - solid progress and hardly noticed by most....well, unnoticed only just for now, I reckon! https://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/chmp-positive-opinion-for-alkindi---infacort--/201712151211035124Z/ f
fillipe
12/12/2017
15:58
hxxps://www.youinvest.co.uk/sharesmagazine/2017-10-26/why-the-drug-space-is-looking-more-attractive DNL mentioned w.r.t Phase III Q1 2018
divinessence
29/11/2017
12:53
Dir Buys, https://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/director-pdmr-shareholding/201711291220198720X/
fillipe
14/10/2017
11:57
An excellent presentation from Diurnal in Manchester this past week, at the Shares Investor Evening. Looks as though the work there is coming to fruition with the possibility of significant upside. f
fillipe
09/5/2017
07:48
Great post RA, as I have come to expect from you!
dusty_coplhopper
09/5/2017
04:21
A COMPELLING CASE… • Diurnal floated on AIM in December 2015 having raised £28.4 million (net of expenses) at 144 pence per Share. • The group is currently on track to become one the few, AIM-listed, UK biotech companies to successfully take a product from concept to commercialisation. • Specifically, Diurnal is on track to becoming a world leading specialty pharma company in endocrinology through its early, 2018 commercial launch of its flagship product Infacort®. • Infacort® is a novel hydrocortisone preparation designed for use in children suffering from adrenal insufficiency; a rare disease which affects 4,000 young children in Europe. There is currently no treatment option in Europe specifically designed to treat these patients. • EMA approval for Infacort® is expected in the short term. This should be transformative for the group as the approval will not only initiate substantial revenues in Q1 2018, but will also make Diurnal an attractive licensing partner for third parties focussed in the endocrinology space (who do not have European commercial operations). • Significant progress has, so far, been made in the European Phase III trial of Chronocort® in congenital adrenal hyperplasia (CAH). • The company is currently on track to commence pivotal clinical programmes for Infacort® and Chronocort® in the US during the next couple of months. • First patient dosed with novel oral testosterone therapy in study evaluating pharmacokinetics, safety and tolerability in male patients with hypogonadism. • According to the leading research firm McKinsey, the addressable market potential of Diurnal’s late-stage product candidates, including further indication extensions in cortisol deficiency, runs into the billions... • Diurnal's product candidates are protected by an extensive patent portfolio, benefitting from a number of granted patents in key jurisdictions, alongside strong protection through orphan drug designations. • The company recently strengthened its Board with the appointment of City heavyweight Richard Bungay as Chief Financial Officer. • Held-to-maturity financial assets, cash and cash equivalents at 31 December 2016 of £25.6m (31 Dec 2015: £33.1m). Thus, the company is sufficiently funded to its first revenues (in Q1 2018) and beyond. • The company boasts a star-studded shareholder base with the likes of Invesco (12.5%), Oceanwood Capital (6.7%), Finance Wales (22%), and Richard Ross (3%). • 92.4% of the 52,210,759 shares in issue are in private hands, leaving a tight ‘free float’. • Current DCF valuation models (across 6 brokerage firms) place Diurnal at a pre-revenue market cap of £139m (253p) – more than double its current market cap of £65m. • Thus, on all the above, and when you consider that the company’s incredible near-commercial pipeline is only valued at £40m (less £25m cash), the shares are profoundly undervalued. .
researchanalyst1
04/1/2016
11:34
The CAH prevalence numbers also appear anomalous particularly as it is more prevalent among African Americans...
mw8156
Chat Pages: 2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180525 01:38:35